Study design
Lead program · Rheumatoid Arthritis
Advancing the science of rheumatoid arthritis.
Raphael’s lead research program focuses on rheumatoid arthritis and the potential role of purified cannabinoid science in inflammatory disease.
Disease context
A science-first lead-program story.
Explore the reported rheumatoid arthritis study, its findings and limitations, and the current research record.
Investigational scientific approach
A framework for research.
Raphael’s research focuses on purified cannabinoid science, receptor biology, signaling and inflammatory pathways. It does not imply regulatory approval or established therapeutic efficacy.
Scientific rationale
Explore biological mechanisms and inflammatory pathways through disciplined research.
Investigational context
Keep research findings distinct from product, regulatory and patient-outcome claims.
Proof-of-concept research
Clinical Trial & Results
The source record describes a completed U.S. single-group proof-of-concept study managed by Citruslabs. It is the central clinical-research record in Raphael’s clinical research history; it is not presented as an approved treatment or a substitute for independent clinical interpretation.
Study population
12 adult patients with high disease activity.
Participant count is reported in the company-hosted study summary; selection criteria require protocol-level review.Use context
0.5 mL daily
Each participant used the formula daily at home, according to the source report.Timing
Week 4
Company materials report improvements evident by Week 4.Source-reported outcomes
What the available study summary reports.
Values below are attributed to company-hosted source material. They should not be read as independently replicated findings, a regulatory conclusion or evidence of an established treatment effect.
Company-reported observations
The following statements reproduce the company’s study-summary wording. They describe preliminary observations in 12 participants, not independently confirmed treatment effects or established commercial-product equivalence.
Raphael’s formula improved DAS28 scores from high disease activity to moderate disease severity by Week 4.
12 adult patients with high disease activity.
91.6% of the participants in the clinical trial stated that they would recommend RaphaWell to other RA patients.
The Disease Activity Score (DAS28)—a comprehensive metric assessing RA disease activity—declined by 19.2%, reflecting a shift in participants from high to moderate disease activity.
By Week 4, Raphael’s formula significantly improved:
- Pain levels.
- The ability to live life to the fullest.
- The ability to pursue passions and hobbies.
- The ability to enjoy relationships.
- The ability to enjoy daily life.
- Sleep rating.
- Relaxation rating.
- DAS28 score.
DAS28
19.2% declineThe source reports movement from high to moderate disease activity, with category changes shown in the linked report.Pain & stiffness
Reported symptom measuresNegative pain outcomes are reported from 75% at baseline to 50%; morning stiffness from 75% to 41.67%.Week 4 context
Daily-life, sleep & relaxation measuresScience Data Updates lists pain, daily-life function, sleep, relaxation and DAS28 among measures reported at Week 4.Biomarkers
No statistically significant change reportedThe available report says blood-biomarker analysis did not reveal statistically significant changes.Current status
Research completed. Preparing for the next stage.
Raphael has completed its proof-of-concept research program and is using the resulting data to inform next scientific and commercial decisions. The studied preparation and the current RaphaWell commercial product are presented separately unless an approved source establishes equivalence.
Investigational research context.
This page does not represent a product approval, an established treatment, or a promise of a future program stage. No future clinical phase, regulatory approval or development milestone is implied.
Publications & source documents
Publications and source records.
Explore Raphael’s publications and research sources, with direct links to the original records.
Clinical source report · January 2025
Rheumatoid arthritis proof-of-concept results
Company-hosted report describing the Citruslabs-managed single-group study, design context and reported outcomes.
Source report; not a peer-reviewed publication.
Company scientific update · January 7, 2025
Science Data Updates
Raphael’s legacy update lists Week 4 pain, daily-life, sleep, relaxation and DAS28 measures, with its own source context.
Company-posted update.
Peer-reviewed preclinical research · July 10, 2025
High CBD extract (CBD-X) modulates inflammation and immune cell activity in rheumatoid arthritis
Miran Aswad, Antonina Pechkovsky, Narmeen Ghanayiem, Haya Hamza and Igal Louria-Hayon. Frontiers in Immunology, 16:1599109. Ex-vivo immune-cell experiments and mouse arthritis models; separate from the 12-person proof-of-concept study.
DOI: 10.3389/fimmu.2025.1599109. Original company-hosted PDF
IP / legal
Intellectual-property source module
Current legal status remains under review.